Enhanced Downstream Processing for a Cell-Based Avian Influenza (H5N1) Vaccine
Vaccines · 29.01.2024 · 12 (2) · 138
DOI: 10.3390/vaccines12020138 ↗Kurz gefasst
Fachartikel in der Zeitschrift Vaccines, online erschienen am 29.01.2024. Verfasst von Fang Li und 16 weiteren Autor:innen. Beteiligte Einrichtung: National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Ministry of Science and Technology of the People's Republic of China, China Hubei Provincial Science Technology Department, Ministry of Science and Technology of the People’s Republic of China.
Abstract (Originalsprache)
H5N1 highly pathogenic avian influenza virus (HPAIV) infections pose a significant threat to human health, with a mortality rate of around 50%. Limited global approval of H5N1 HPAIV vaccines, excluding China, prompted the need to address safety concerns related to MDCK cell tumorigenicity. Our objective was to improve vaccine safety by minimizing residual DNA and host cell protein (HCP). We developed a downstream processing method for the cell-based H5N1 HPAIV vaccine, employing CaptoTM Core 700, a multimodal resin, for polishing. Hydrophobic-interaction chromatography (HIC) with polypropylene glycol as a functional group facilitated the reversible binding of virus particles for capture. Following the two-step chromatographic process, virus recovery reached 68.16%. Additionally, HCP and DNA levels were reduced to 2112.60 ng/mL and 6.4 ng/mL, respectively. Western blot, high–performance liquid chromatography (HPLC), and transmission electron microscopy (TEM) confirmed the presence of the required antigen with a spherical shape and appropriate particle size. Overall, our presented two-step downstream process demonstrates potential as an efficient and cost-effective platform technology for cell-based influenza (H5N1 HPAIV) vaccines.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- National Engineering Technology Research Center for Combined Vaccines, Wuhan 430207, China.
- Wuhan Institute of Biological Products Co., Ltd., Wuhan 430207, China.
- National Key Laboratory for Novel Vaccines Research, Development of Emerging Infectious Diseases, Wuhan 430207, China.
- Hubei Provincial Vaccine Technology Innovation Center, Wuhan 430207, China.
- China National Biotec Group Company Limited, Beijing 100029, China.
ORCID-Profile: Fang Li, Zhegang Zhang, Xiaoming Yang
Förderung
- Ministry of Science and Technology of the People's Republic of China
- China Hubei Provincial Science Technology Department
- Ministry of Science and Technology of the People’s Republic of China
Zitieren
APA
Li, F., Liu, B., Xiong, Y., Zhang, Z., Zhang, Q., Qiu, R., Peng, F., Nian, X., Wu, D., Li, X., Liu, J., Li, Z., Tu, H., Wu, W., Wang, Y., Zhang, J., & Yang, X. (2024). Enhanced Downstream Processing for a Cell-Based Avian Influenza (H5N1) Vaccine. Vaccines, 12(2), 138. https://doi.org/10.3390/vaccines12020138
Vancouver
Li F, Liu B, Xiong Y, Zhang Z, Zhang Q, Qiu R, et al. Enhanced Downstream Processing for a Cell-Based Avian Influenza (H5N1) Vaccine. Vaccines. 2024;12(2):138. doi:10.3390/vaccines12020138
BibTeX
@article{Li2024,
author = {Li, Fang and Liu, Bo and Xiong, Yu and Zhang, Zhegang and Zhang, Qingmei and Qiu, Ran and Peng, Feixia and Nian, Xuanxuan and Wu, Dongping and Li, Xuedan and Liu, Jing and Li, Ze and Tu, Hao and Wu, Wenyi and Wang, Yu and Zhang, Jiayou and Yang, Xiaoming},
title = {Enhanced Downstream Processing for a Cell-Based Avian Influenza (H5N1) Vaccine},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {2},
pages = {138},
doi = {10.3390/vaccines12020138}
}
EUVIMED